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Abstract
Cancer‐associated fibroblasts (CAFs) constitute a major compartment of the tumor
microenvironment. In the present study, we investigated the role for CAFs in breast
cancer progression and underlying molecular mechanisms. Human breast cancer
MDA‐MB‐231 cells treated with the CAF‐conditioned media manifested a more
proliferative phenotype, as evidenced by enhanced messenger RNA (mRNA) ex-
pression of Cyclin D1, c‐Myc, and proliferating cell nuclear antigen. Analysis of data
from The Cancer Genome Atlas revealed that fibroblast growth factor‐2 (FGF2)
expression was well correlated with the presence of CAFs. We noticed that the
mRNA level of FGF2 in CAFs was higher than that in normal fibroblasts. FGF2 exerts
its biological effects through interaction with FGF receptor 1 (FGFR1). In the breast
cancer tissue array, 42% estrogen receptor‐negative patients coexpressed FGF2 and
FGFR1, whereas only 19% estrogen receptor‐positive patients exhibited coexpres-
sion. CAF‐stimulated MDA‐MB‐231 cell migration and invasiveness were abolished
when FGF2‐neutralizing antibody was added to the conditioned media of CAFs. In a
xenograft mouse model, coinjection of MDA‐MB‐231 cells with activated fibroblasts
expressing FGF2 dramatically enhanced tumor growth, and this was abrogated by
silencing of FGFR1 in cancer cells. In addition, treatment of MDA‐MB‐231 cells with
FGF2 enhanced expression of Cyclin D1, a key molecule involved in cell cycle pro-
gression. FGF2‐induced cell migration and upregulation of Cyclin D1 were abolished
by siRNA‐mediated FGFR1 silencing. Taken together, the above findings suggest
that CAFs promote growth, migration and invasion of MDA‐MB‐231 cells via the
paracrine FGF2‐FGFR1 loop in the breast tumor microenvironment.
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1 | INTRODUCTION
The stromal cells represent an important component of the tumor
microenvironment and contribute to the progression of cancer.1,2
Among several types of stromal cells, fibroblasts are prevalent in the
tumor microenvironment. Cancer cells activate stromal fibroblasts
into cancer‐associated fibroblasts (CAFs) through stimulation of
paracrine growth factors.1 CAFs are morphologically and functionally
different from normal fibroblasts (NFs) as indicated by their in-
creased rate of proliferation and differential expression of extra-
cellular matrix constituents and growth factors.1,3 CAFs have
significant roles in promotion of growth and invasiveness of cancer
cells.4 It has been reported that tumors with abundant CAFs have
poorer prognosis than those with less CAFs.5 In particular, triple‐
negative breast cancer (TNBC) patients with stroma‐rich tumors
have a worse outcome than those with stroma‐poor tumors for
overall survival.6 Therefore, molecules secreted by CAFs including
CXCL14 and CCL5 are considered potential therapeutic targets for
the treatment of TNBC.7 However, despite emerging evidence for
the crucial role of CAFs in tumor microenvironment, the molecular
mechanisms by which CAFs regulate proliferation, progression and
invasiveness of cancer cells are not fully understood.
CAFs secrete a distinct set of growth factors and cytokines
which promote survival, growth, and progression of cancer cells.8‐11
Fibroblast growth factors (FGFs) are a family of multifunctional
growth factors involved in a plethora of cellular activities, ranging
from proliferation, survival, migration, and differentiation to angio-
genesis and tissue repair. Over 20 different FGF isoforms have been
identified in mammals, some of which play a role in the pathogenesis
of cancer. For instance, stromal expression of FGF10 affects invasive
behavior of breast cancer.12 FGF1 secreted by ovarian CAFs stimu-
lates cell proliferation and migration signaling in a FGF receptor
(FGFR) 4‐dependent fashion.13 In addition, FGF2 has been known as
a major growth factor derived from CAFs surrounding breast cancer
tissue.3,14 Notably, CAFs isolated from hormone‐independent tumors
express higher levels of FGF2 compared with hormone‐dependent
counterparts.15
FGF2 is a classical survival factor in multiple cell types.16 In-
appropriate overexpression of FGF2 and its receptors causes aber-
rant cell proliferation in various malignancies including breast,
ovarian, and skin cancer.17 The biological activity of the FGF2
requires the presence of FGFRs to transduce specific signal
transduction.18 The mammalian FGFR family proteins are encoded by
four distinct genes (Fgfr1‐4), and their interaction with the corre-
sponding ligand determines the specificity of FGF‐induced down-
stream signaling.19
Of the four FGFRs, FGFR1 has been known to exhibit high af-
finity for FGF2.20 However, the cross‐talk between FGF2 secreted
from CAFs and FGFR1 in breast cancer cells has not been elucidated
yet. This prompted us to investigate the potential role of the
FGF2‐FGFR1 axis in breast tumor microenvironment. Here, we
report that CAF‐derived FGF2 stimulates breast cancer cell pro-
liferation, migration, and progression via FGFR1 signaling.
2 | METHODS AND MATERIALS
2.1 | Reagents and antibodies
Dulbecco's modified Eagle's medium (DMEM), Rosewell Park Mem-
orial Institute (RPMI) 1640 medium, and minimum essential medium
(MEM) were purchased from Gibco BRL (Grand Island, NY). TRIzol
was obtained from Invitrogen (Carlsbad, CA). Primary antibodies for
FGFR1 and Cyclin D1 were products of Cell Signaling Technology
(Danvers, MA). α‐Smooth muscle actin (α‐SMA) antibody was
obtained by Abcam (Cambridge, UK). Antibodies against FGFR2,
and β‐actin were purchased from Santa Cruz Biotechnology, Inc
(Santa Cruz, CA). The bicinchoninic acid (BCA) protein assay reagent
was a product of Pierce Biotechnology (Rockfold, IL).
2.2 | Tissue microarray
Human paraffin‐embedded breast cancer tissue array with matched
adjacent normal breast tissue (US biomax, Inc; Rockville, MD) was
subjected to immunohistochemical and immunofluorescent analysis.
Immunohistochemical analysis was performed by Abion CRO (Seoul,
South Korea). Four‐μm sections of 10% formalin‐fixed, paraffin‐
embedded tissues were placed on glass slides and deparaffinized
three times with xylene and rehydrated through graded alcohol bath.
The deparaffinized sections were heated by using microwave and
boiled twice for 6 minute in 10mM citrate buffer (pH 6.0) for antigen
retrieval. To diminish nonspecific staining, each section was treated
with 3% hydrogen peroxide and 4% peptone casein blocking solution
for 15minute. Slides were then incubated with α‐SMA antibody at
room temperature for 40minute in Tris‐buffered saline with 0.1%
Tween 20 (TBST) and blots were developed using horseradish per-
oxidase (HRP)‐conjugated secondary antibody. The peroxidase
binding site were detected by staining with 3,3′‐diaminobenzidine
tetrahydrochloride. Finally, counterstaining was performed using
Mayer's hematoxylin.
For immunofluorescence analysis, tissue blocks were depar-
affinized with xylene. Following antigen retrieval by heated citrate
buffer, sections were permeabilized and blocked according to the
standard protocol. After overnight incubation at 4℃ with fluorescent
conjugated anti‐FGF2 or anti‐FGFR1 antibody, the tissue section was
washed with phosphate‐buffered saline (PBS) and then analyzed
under a fluorescence microscope.
2.3 | Immunofluorescence staining of cultured
fibroblasts
NFs and CAFs were seeded at 5 × 103 cells per well in an eight
chamber plate. After overnight incubation, cells were fixed with
fixation solution containing 95% methanol and 5% acetic acid
(20minute). The cells were then washed in PBS (twice 5minute
each), permeabilized with 0.2% triton X‐100 (5 minute), washed in
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PBS (twice 5minute each), and blocked with 5% bovine serum
albumin (BSA) in PBS (30minute). Polyclonal rabbit anti‐α‐SMA,
diluted at 1:100 with 1% BSA in PBS, was applied overnight at 4℃.
This was followed by washing cells in PBS (twice 5minute each) and
then incubation for 1 hour at room temperature with fluorescein
isothiocyanate‐conjugated anti‐rabbit IgG secondary antibody di-
luted at 1:1000 with 1% BSA in PBS. After washing (twice 5minute
each), cells were treated with propidium iodide. The expression of
α‐SMA was detected using a confocal microscope (Leica micro-
systems; Wetzlar, Germany).
2.4 | Gene expression profile analysis
To determine the relationship between FGF2 and α‐SMA genes in
breast cancers, we selected “Breast Invasive Carcinoma (Provisional)”
data set publically available from TCGA data portal (www.cbioportal.
org). The clinical significance of ACTA2 (α‐SMA) and FGF2 mRNA
expression was evaluated by calculating the Spearman's correlation
coefficient.
2.5 | Cell culture
Human breast cancer (MCF‐7, MDA‐MB‐231, and MDA‐MB‐468)
cell lines were maintained in RPMI 1640 and DMEM supple-
mented with 10% fetal bovine serum (GenDEPOT; Barker, TX)
and 100 ng/mL penicillin/streptomycin/fungizone mixture at
37℃ in a humidified atmosphere of 5% CO2/95% air. CCD‐
1068sk breast NFs were maintained in MEM supplemented with
10% fetal bovine serum (GenDEPOT) and 100 ng/mL penicillin/
streptomycin/fungizone mixture. Primary NFs and CAFs cells
(Asterand Bioscience; Detroit, MI) were incubated with 10% fatal
bovine serum (Gibco BRL; Grand Island, NY) and 100 ng/mL
penicillin/streptomycin/fungizone mixture and other supple-
ments. The cells were plated at an appropriate density according
to each experimental scale. All human cell lines have been au-
thenticated within the last 3 years, and experiments were per-
formed with mycoplasma‐free cells.
2.6 | Collection of conditioned media
CAFs and NFs were seeded on 100mm dishes at 1 × 106 cells/mL.
Culture medium was removed 24 hour after seeding, and cells were
washed once with PBS followed by addition of 8 mL of serum‐free
medium per well. After 48 hour of incubation, the conditioned
media (CM) was collected and passed through 0.2 μm membrane
syringe filter to remove any residual cells and debris. For neu-
tralization of FGF2 in the CM of CAFs, CM was preincubated with
25 μg/mL of human FGF2 antibody or its immunoglobulin G (IgG)
control (R&D systems; Minneapolis, MN) for 1 hour at room
temperature.
2.7 | Enzyme‐linked immunosorbent assay
The concentration of FGF2 was determined by the enzyme‐linked im-
munosorbent assay (ELISA) assay (R&D systems). CM of CAFs and NFs
was collected and concentrated with Amicon Ultra 50 kDa centrifugal
filters (Milipore; Burlington, MA). The concentrated CM was used for
measurement of the FGF2 level according to the manufacturer's protocol.
2.8 | Cell migration assay
Cell migration was measured using the culture‐inserts (2 × 0.22 cm2)
supplied from Ibidi GmbH (Regensburg, Germany). To create a wound
gap, 100 μL of 1 ×105 cancer cells were seeded on the culture‐inserts,
which were gently removed using sterile tweezers following an overnight
incubation. Cells were then exposed to CMs of fibroblasts (NF‐CM and
CAF‐CM) with or without 5 μM of FGF2‐neutralizing antibody (Millipore;
Darmstadt, Burlington, MA) for 24hour. The progression of wound clo-
sure was monitored, and distance between gaps was measured under the
microscope (Nikon; Tokyo, Japan). All assays were performed in triplicate.
2.9 | Cell invasion assay
The 24‐well transwell chamber plate with pores of 8 μm in diameter
was used to determine the invasive capability of the cells. Fibroblasts
(2 × 104 cells/well) were seeded in the lower compartment. After
incubation for 24 hour, cancer cells (1 × 104 cells/well) were seeded
in the insert. The lower chamber beneath the insert membrane was
incubated in 600 μL of 1% DMEM supplemented with 1% fetal bovine
serum in the absence or presence of 5 μM of FGF2‐neutralizing
antibody. After 36‐hour incubation, cells on the upper surface of the
membrane were removed by wiping with cotton swabs, and the
invaded cells were fixed with 100% methanol and stained with 0.05%
crystal violet (Sigma‐Aldrich; St Louis, MO). The number of invaded
cells was counted in three high power fields under a microscope. The
experiment was repeated three times independently.
2.10 | Three‐dimensional invasion assay (spheroid
invasion assay)
The spheroid invasion assay was performed using a 96‐well 3D
spheroid BME cell invasion assay kit (Trevigen; Gaithersburg, MD).
Briefly, cells were resuspended in the spheroid formation extra-
cellular matrix and MDA‐MB‐231 cells (1 × 103) and control‐ or
transforming growth factor beta (TGF‐β)‐activated CCD‐1068sk fi-
broblasts (1 × 103) were plated in the round bottom low attachment
96‐well plate. After the cells were left to form spheroids for 3 days,
invasion matrix was added to each well and incubated at 37℃ for
3 hour followed by addition of culture medium. Spheroids were vi-
sualized under a bright field microscope, 1 day and 6 days after
addition of the invasion matrix. Relative invasion was analyzed by
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using Image J calculating the threshold the spheroid area and mea-
suring the number of pixels within the area.
2.11 | Western blot analysis
Cells were lysed in radioimmunoprecipitation assay lysis buffer (150mM
NaCl, 0.5% Triton ×100, 50mM Tri‐HCl [pH 7.4], 25mM NaF, 20mM
EGTA, 1mM, 1mM Na3VO4, 0.1mM phenylmethylsulfonyl fluoride, and
protease inhibitor cocktail tablets) for 15minute on ice followed by
centrifugation at 13000 g for 20minute. The protein concentration of
the supernatant was measured by using BCA reagent (Thermo Fisher
Scientific; Rockford, IL). Protein (30 μg) was separated by 8% to 12%
sodium dodecyl sulfate‐polyacrylamide gel electrophoresis gel and
transferred to the polyvinylidene difluoride membrane (Gelman
Laboratory; Ann Arbor, MI). The blots were blocked with 5% nonfat dry
milk/TBST for 1 hour at room temperature. The membranes were
incubated for 4 hour at room temperature with 1:1000 dilution of
polyclonal antibody of FGFR1, P‐FRS2α, Cyclin D1, lamin B1, and actin.
The blots were rinsed three times with TBST for 10minute each.
Washed blots were incubated with 1:5000 dilutions of HRP‐conjugated
secondary antibody (Thermo Fisher Scientific) for 1 hour and washed
again three times with TBST buffer. The transferred proteins were
visualized with an enhanced chemiluminescence detection kit
(Amersham Pharmacia Biotech; Buckinghamshire, UK).
2.12 | Small interfering RNA transfection
Small interfering RNA (siRNA) oligonucleotides targeting for FGFR1 and
FGF2 were purchased from Genolution Pharmaceuticals (Seoul, South
Korea). The sense and antisense strands of FGFR1 and FGF2 used are as
follows (forward and reverse, respectively): FGFR1; 5′‐AUUCAAACCU
GACCACAGA‐3′ and 5′‐UCUGUGGUCAGGUUUGAAU‐3′, FGF2; 5′‐UA
UACUGCCCAGUUCGUUUCAGUGC‐3′ and 5′‐GCACUGAAACGAACU
GGGCAGUAUA‐3′. MDA‐MB‐231 cells (4 × 105/60‐mm dish) were
transfected with 25 nM of specific or scrambled siRNA oligonucleotides
using Lipofectamine RNAiMAX according to manufacturer's instructions
(Invitrogen).
2.13 | Reverse transcription‐polymerase chain
reaction
Total RNA was isolated from each cell by using TRIzol reagent (In-
vitrogen; Carlsbad, CA) according to the manufacturer's protocol. One
µg of total RNA was reverse‐transcribed with murine leukemia virus
reverse transcriptase (Promega; Madison, WI). The primers employed
were (forward and reverse, respectively): α‐SMA, 5′‐AGCGACCCTAAA
GCTTCCCA‐3′ and 5′‐CATAGAGAGACAGCACCGCC‐3′, 791 bp;
FAP‐α, 5′‐AGTTTCAGCGACTACGCCAA‐3′ and 5′‐GGAAAGCTGTTCC
TCGACCA‐3′, 379 bp; Cyclin D1, 5′‐ACCTGGATGCTGGAGGTCT‐3′
and 5′‐GCTCCATTTGCAGCAGCTC‐3′, 241 bp; c‐Myc, 5′‐AGCAGCGAC
TCTGAGGAGGAACAAGAA‐3′ and 5′‐AGGTAGTCCTTCCGAGTGG
A‐3′, 216 bp; PCNA, 5′‐ CTTTTCTGTCACCAAATTTGTACC‐3′ and 5′‐A
ACTGCATTTAGAGTCAAGACCC‐3′, 206 bp; MMP2, 5′‐GGCCAAGTG
GTCCGTGTG‐3′ and 5′‐GAGGCCCCATAGAGCTCC‐3′, 692 bp; MMP9,
5′‐CACTGTCCACCCCTCAGAGC‐3′ and 5′‐GCCACTTGTCGGCGATAA
GG‐3′, 263 bp; FGFR1, 5′‐AACCTGCCTTATGTCCAGATCT‐3′ and 5′‐A
GGGGCGAGGTCATCACTGC‐3′, 209 bp; GAPDH, 5′‐AAGGTCGGAGT
CAACGGATTT‐3′ and 5′‐GCAGTGAGGGTCTCTCTCT‐3′, 1053 bp.
Amplification products were resolved by 1% to 2% agarose gel elec-
trophoresis, stained with ethidium bromide, and photographed under
ultraviolet light.
2.14 | In vivo xenograft assay
Female Balb/c (nu/nu) mice, 5 weeks of age, were purchased from
Orientbio (Seoul, South Korea) and acclimatized for 1 week under
standard temperature, humidity, and time lighting conditions at the
animal care facility. All animal experiments were conducted in ac-
cordance with the Guide for the Care and Use of Laboratory Animals,
and approved by the Institutional Animal Care and Use Committee of
Seoul National University. After 1 week of adaptation, shmock‐ or
shFGFR1‐knockdown‐MDA‐MB‐231 cells and control‐ or TGF‐β‐
activated CCD‐1068sk fibroblasts were coinjected subcutaneously
into the flank at a density of 5 × 106 cells in 75 μL PBS and 75 μL
Matrigel). Three weeks after injection, tumor volumes were calcu-
lated according to the formula: 0.5 × (length) × (width)2. Mice were
killed after 7 weeks of tumor injection. All the tumors were formalin‐
fixed, and paraffin‐embedded for hematoxylin and eosin (H&E)
staining and Masson's trichrome staining.
2.15 | Immunohistochemical analysis
The dissected xenograft tumor tissues were prepared for
immunohistochemical analysis to detect the expression of
Cyclin D1 and proliferating cell nuclear antigen (PCNA).
Immunohistochemical analysis was performed by Abion CRO
(Seoul, South Korea). Four‐μm sections of 10% formalin‐fixed,
paraffin‐embedded tissues were placed on glass slides and de-
paraffinized three times with xylene and rehydrated through
graded alcohol bath. The deparaffinized sections were heated by
using microwave and boiled twice for 6 minute in 10 mM citrate
buffer (pH 6.0) for antigen retrieval. To diminish nonspecific
staining, each section was treated with 3% hydrogen peroxide
and 4% peptone casein blocking solution for 15 minute. For the
detection of respective protein expression, slides were incubated
with Cyclin D1 or PCNA antibody at room temperature for
40 minute in TBST, and blots were then developed using HRP‐
conjugated goat anti‐rabbit or anti‐mouse secondary antibody,
respectively. The peroxidase binding was detected by staining
with 3,3′‐diaminobenzidine tetrahydrochloride. Finally, counter-
staining was performed using Mayer's hematoxylin.
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2.16 | Statistical analysis
When necessary, data were represented as means ± SD at least
three independent experiments, and statistical analysis between
groups was performed using the Student t test. *P < .05;
**P < .01; ***P < .005.
3 | RESULTS
3.1 | CAFs are abundant in breast cancer tissues as
evidenced by increased expression of the activated
fibroblast marker α‐SMA
CAFs are characterized by their overexpression of α‐SMA, a cytos-
keletal protein associated with smooth muscle cells21 which con-
tributes to morphological transformation from a spindle‐like to a
stellate shape. As shown in Figure 1A, analysis of the human breast
cancer tissue array revealed increased expression of α‐SMA com-
pared with normal adjacent tissue. In particular, 95% (37 out of 39)
estrogen receptor (ER)‐negative breast cancer patients expressed a
high level of α‐SMA while 55% (33 out of 60) of ER‐positive breast
cancer patients expressed α‐SMA. The higher expression of α‐SMA in
breast tumors than adjacent normal tissues was verified by im-
munohistochemical analysis (Figure 1B). We observed α‐SMA‐
positive myoepithelial cells surrounding normal mammary glands
which was also described in other studies.22,23 While NFs showed the
typical spindle‐shape morphology, CAFs displayed a more hetero-
geneous appearance with branched cytoplasm surrounding speckle
nucleus (Figure 1C). The identity of CAFs and NFs was verified by
their differential expression of genes encoding α‐SMA and fibroblast
activating protein‐α (FAP‐α) as determned by RT‐PCR (Figure 1D).
The prevalent overexpression of α‐SMA in CAFs was also verified by
immunofluorescence analysis (Figure 1E).
F IGURE 1 Identification of CAFs in human breast cancer tissues. A, Invasive breast carcinomas from a tumor tissue microarray were stained
for α‐SMA. H&E images were provided by US Biomax Inc. B, The expression levels of α‐SMA between infiltrating ductal carcinoma and adjacent
normal tissues of breast cancer patients were compared by immunohistochemical analysis. Magnification, ×200. C, Isolated CAFs have distinct
morphology characterized by large and plump cells (red arrows) distinguished from NFs which are thin, wavy, and small spindle cells (yellow
arrow). Bars, 40 μm. D, The mRNA expression of activated fibroblast markers, such as α‐SMA and FAP‐α, was measured by RT‐PCR in NFs and
CAFs. E, Expression of α‐SMA in NFs and CAFs was determined by immunofluorescent staining. Bars = 100 μm. CAFs, cancer‐associated
fibroblasts; H&E, hematoxylin and eosin; mRNA, messenger RNA; NFs, normal fibroblasts; RT‐PCR, reverse transcription‐polymerase chain
reaction; α‐SMA, α‐smooth muscle actin [Color figure can be viewed at wileyonlinelibrary.com]
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3.2 | CAFs stimulate proliferation and invasiveness
of MDA‐MB‐231 breast cancer cells
To determine whether CAFs are involved in cancer cell prolifera-
tion, we collected CM from CAFs (CAF‐CM) and NFs (NF‐CM), and
then both media were treated to breast cancer cells. CAF‐CM
dramatically enhanced the ability of ER‐negative MDA‐MB‐231
cells to migrate compared with NF‐CM, whereas CAF‐CM barely
induced migration of ER‐positive MCF‐7 cells (Figure 2A). Like-
wise, MDA‐MB‐231 cells incubated with CAF‐CM were more
proliferative than MCF‐7 cells (data not shown). Cyclin D1, a well‐
known cell proliferation marker, is involved in cell migration, and
hence ultimately cancer metastasis.24,25 Incubation of MDA‐MB‐
231 cells in the presence of CAF‐CM induced transient upregula-
tion of Cyclin D1 (Figure 2B) and its mRNA transcript (Figure 2C).
In addition, expression of two other proliferation marker genes,
c‐Myc and PCNA was also enhanced upon stimulation with CAF‐CM
(Figure 2C). Moreover, MDA‐MB‐231 cells cocultured with CAFs
induced expression of these genes and also invasion marker genes
(MMP2 and MMP9) and the epithelial to mesenchymal transition
marker gene, SNAI1 (Figure 2D).
3.3 | FGF2 production in CAFs is associated with
MDA‐MB‐231 cell migration and invasiveness
To address which secreted factors are involved in breast cancer
progression, fibroblast expression of genes encoding representative
oncogenic members of FGF family, FGF1, FGF2, and FGF1026‐28 was
determined by RT‐PCR. As shown in Figure 3A, FGF2 accumulation
was most dramatically increased in primary CAFs compared with that
in NFs. This result is consistent with other studies demonstrating that
CAFs overexpress FGF2 in colon cancer and lung adenocarcino-
ma.29,30 To investigate the correlation between FGF2 expression and
fibrous stromal characteristics of breast cancer, we analyzed the
expression levels of FGF2 and α‐SMA in breast cancer patients, and
observed a significant correlation (Spearman correlation coefficient;
.24, P = 1.43e−13; Figure 3B).
To assess the functional role of FGF2 in CAF‐CM‐induced breast
cancer cell migration, a wound healing assay was conducted by using
FGF2‐neutralizing antibody. The concentration of FGF2, determined
by ELISA, was much higher in CM from CAFs, compared with that in
CM from NFs (Figure 3C). As illustrated in Figure 3D, CAF‐CM‐
promoted MDA‐MB‐231 cell migration was significantly reduced
F IGURE 2 Enhancement of breast cancer cell proliferation and migration by CAFs. A, Migrative ability of MDA‐MB‐21 cells was measured
by the wound healing assay. Migration distance of cells stimulated with CAF‐CM was increased compared with that of those cells treated with
NF‐CM. B and C, MDA‐MB‐231 cells were incubated with CAF‐CM for the indicated time periods, and the protein levels of Cyclin D1 was
assessed by Western blot analysis (B). The mRNA expression of cell proliferation markers was analyzed by RT‐PCR (C). D, MDA‐MB‐231 cells
were cocultured with CAFs and NFs for 24 hour, and the mRNA levels of proliferative and invasive markers were determined by RT‐PCR. Data
are means ± SD. *P < .05; **P < .01; ***P < .005 . CAFs, cancer‐associated fibroblasts; CM, conditioned medium; mRNA, messenger RNA;
NFs, normal fibroblasts; RT‐PCR, reverse transcription‐polymerase chain reaction [Color figure can be viewed at wileyonlinelibrary.com]
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when FGF2‐neutralizing antibody was added. Likewise, antibody
neutralization of FGF2 abolished the invasiveness of these cells co-
cultured with CAFs (Figure 3E).
TGF‐β is a representative inducer of fibroblast activation.31 We
established TGF‐β‐activated fibroblasts (CCD‐1068sk‐TGF‐β) by pre-
incubating CCD‐1068sk‐immortalized fibroblasts with TGF‐β for
4 days.32 TGF‐β‐activated fibroblasts acquires altered gene signatures
and exhibit CAF‐like phenotypic characteristics.33 Like primary CAFs,
these TGF‐β‐activated fibroblasts overexpressed a CAF marker gene, α‐
SMA as well as FGF2 (Figure 3F). Notably, MDA‐MB‐231 cells attained
enhanced invasiveness when cocultured with CAF‐like CCD‐1068sk‐
TGF‐β fibroblasts in 3D invasion matrix (Figure 3G), and this was nul-
lified by FGF2‐neutralizing antibody (Figure 3H).
Based on above findings, we speculate that FGF2 secreted by
CAFs binds to a specific receptor present in the MDA‐MB‐231
cells, thereby regulating their proliferation, and plasticity. To
identify the appropriate receptor expressed in MDA‐MB‐231 cells
capable of mediating oncogenic signal transduction triggered by
CAF‐derived FGF2 in a paracrine manner, the protein expression
levels of all four FGFR isoforms (FGFR1, FGFR2, FGFR3, and
FGFR4) were measured. As shown in Figure 4A, FGFR1 was found
to be predominantly expressed in MDA‐MB‐231 cells, qualifying
them for paracrine interaction with CAFs. Expression of FGFR1
(Figure 4A) and its mRNA transcript (Figure 4B) was also detect-
able in MDA‐MB‐468 cells. Unlike MDA‐MB‐231 cells, however,
MDA‐MB‐468 cells express FGF2 as well (Figure 4B), a gene
F IGURE 3 Effects of FGF2 produced by CAFs breast cancer cell migration and invasion. A, The mRNA expression of some representative
FGFs was determined by RT‐PCR in NFs and CAFs. B, Correlation between the mRNA levels of FGF2 and α‐SMA in breast cancer patients. To
analyze the relationship between FGF2 and α‐SMA in breast cancers, we obtained the data from TCGA, Provisional by using www.cbioportal.org.
Spearman's correlation coefficient represents positive association between to genes. C, Secretion of FGF2 in NFs and CAFs was measured by
the ELISA assay. D, Migrative ability of MDA‐MB‐231 cells with and without FGF2 antibody treatment was measured by the wound healing
assay. The cells were exposed to CAF‐CM in the absence or presence of FGF2‐neutralizing antibody for 24 hour. Bars = 500 μm. E, The extent of
cancer cell invasion was measured by a transwell cell invasion assay in MDA‐MB‐231 cells. Bars = 100 μm. F, The mRNA expression of activated
fibroblast markers was determined by RT‐PCR in control and TGF‐β‐stimulated CCD‐1068sk fibroblasts which were preincubated over 4 days
with recombinant TGF‐β. G, Bright field micrographs of spheroidal aggregates that contain MDA‐MB‐231 cells cocultured with control or
TGF‐β‐stimulated CCD‐1068sk fibroblasts. Protrusions of invasive cancer cells were marked by arrows. Bars = 200 μm. H, Effects of FGF2
antibody neutralization on TGF‐β‐stimulated formation of spheroidal aggregates. Data are means ± SD. CAFs, cancer‐associated fibroblasts;
ELISA, enzyme‐linked immunosorbent assay; FGF, fibroblast growth factor; mRNA, messenger RNA; NFs, normal fibroblasts; RT‐PCR, reverse
transcription‐polymerase chain reaction; TGF‐β, transforming growth factor beta; α‐SMA, α‐smooth muscle actin. *P < .05; **P < .01; ***P < .005
[Color figure can be viewed at wileyonlinelibrary.com]
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encoding a potential ligand of FGFR1, suggesting an autocrine
involvement of latter cells.
Tissue microarray analysis showed that expression of FGF2 and
FGFR1 was elevated in breast cancer tissues compared with normal
adjacent tissues (Figure 4C). In particular, 42% (15 out of 36) of
ER‐negative patients coexpressed FGF2 and FGFR1, while the same
coexpression was observed in only 19% (12 out of 62) of ER‐positive
patients (Figure 4D). By analyzing publicly available gene expression
profile data (GSE37614), CAFs from TNBC patients were found to
have downregulated FGFR1 and upregulated FGF2 expression profiles,
which further supports the possible paracrine signaling mediated by
their protein products in ER‐negative breast cancer (Figure S1).
3.4 | FGF2 promotes migration of MDA‐MB‐231
cells through FGFR1
To determine whether FGF2 could accelerate proliferation and mi-
gration of MDA‐MB‐231 cells through activation of FGFR1 signaling,
these cells were incubated with human recombinant FGF2. As shown
in Figure 5A, the expression of Cyclin D1 was transiently increased in
response to FGF2 stimulation. FGFR1 gene silencing abrogated
the FGF2‐induced Cyclin D1 expression at both transcriptional
(Figure 5B) and translational (Figure 5C) levels. Furthermore, FGFR1‐
siRNA‐transfected MDA‐MB‐231 cells exhibited complete suppression
of Akt phosphorylation (Figure 5E) and migration (Figure 5E).
3.5 | Activated fibroblasts promote xenograft
tumor growth via the FGF2‐FGFR1 signaling
To specifically figure out whether FGF2‐expressing CAFs could enhance
breast tumor growth via FGFR1 signaling, we utilized lentivirus‐mediated
RNA interference to stably knockdown FGFR1 in MDA‐MB‐231 cells
(referred to as shFGFR1‐MDA‐MB‐231). Control cancer cells were
transduced with scrambled short hairpin RNA (shmock‐MDA‐MB‐231).
Athymic nude mice were then coinjected with control‐ or TGF‐β‐
activated CCD‐1068sk fibroblasts and shmock‐ or shFGFR1‐MDA‐
MB‐231 cells. MDA‐MB‐231 cells coinjected with TGF‐β‐activated CCD‐
1068sk fibroblasts formed xenograft tumors (Figure 6A) which were
grown much faster (Figure 6B) and larger (Figure 6C) than those derived
from the MDA‐MB‐231 cells coinjected with unactivated fibroblasts. A
complex collagen network reflects the presence of fibroblasts which can
be depicted by blue staining in Masson's trichrome stain (Figure 6D).
F IGURE 4 Differential expression of FGFR isoforms in breast cancer cell lines. A and B, The expression of FGFRs and their mRNA transcripts
in different breast cancer cells was analyzed by Western blot (A) and RT‐PCR (B) analyses, respectively. C, Immunofluorescent staining of
samples from a breast cancer tissue array was performed using anti‐FGFR1 and anti‐FGF2 antibodies. Images of H&E stained tissue sections
were provided by US Biomax Inc. Bars = 200 μm. D, The proportion of tumor tissues vs adjacent normal tissues coexpressing FGF2 and FGFR1
was quantified. FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; H&E, hematoxylin and eosin; mRNA, messenger RNA;
RT‐PCR, reverse transcription‐polymerase chain reaction [Color figure can be viewed at wileyonlinelibrary.com]
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There was increased stromal compartment as indicated by blue‐colored
background in Masson's trichrome stain in tumors coinjected with acti-
vated fibroblasts and shmock‐MDA‐MB‐231 cells (group 3; Figure 6D).
These tumors also exhibited significantly elevated expression of the
proliferative markers Cyclin D1 and PCNA. In addition, the upregulated
expression of FGFR1 as well as Cyclin D1 was evident as assessed by
Western blot analysis (Figure 6E). These data indicate that FGF2 pro-
duced by activated fibroblasts could facilitate growth of adjacent cancer
cells in breast tumor microenvironment via the FGFR1 signaling.
4 | DISCUSSION
Mounting evidence supports the cross‐talk between cancer cells and
several types of stromal cells including fibroblasts, immune cells and
endothelial cells, in the tumor microenvironment.34 Tumors which con-
tain large proportion of stromal cells have been associated with poor
prognosis, independently of other clinicopathological parameters in
breast cancer patients.6 CAFs represent a major component of stroma in
the tumor microenvironment, and play an important role in tumor de-
velopment and progression.1
Among many factors secreted in tumor microenvironment, TGF‐β is
recognized as a master regulator of the trans‐differentiation of stromal
fibroblasts in the mammary tumor microenvironment.3,35 Promotion of
fibroblasts to activated myofibroblasts by TGF‐β confers manifestation
of CAF genotypes including elevated α‐SMA expression.36 CAFs in-
crease the frequency of colon tumor‐initiating cells, and this effect is
dramatically enhanced by TGF‐β signaling.32 Furthermore, poor prog-
nostic colorectal cancer subtypes share a gene program induced by
TGF‐β in tumor stromal cells.32 TGF‐β1 protein levels are also con-
sidered as prognostic marker for breast cancer, especially for TNBC.37
It has been reported that CAFs contribute to cell proliferation,
angiogenesis and metastasis in breast cancer.11,38,39 However, a
complete understanding of stromal‐cancer cell interactions has a long
way to go. In tumor microenvironment, CAFs are known to interact
with other cells including cancer cells in a paracrine manner.14 In our
present study, CAF‐CM rendered TNBC MDA‐MB‐231 cells more
proliferative than non‐TNBC MCF‐7 cells. This differential effect of
CAF‐CM on breast cancer cell proliferation has been reported in
other studies, demonstrating that MCF‐7 cells are less sensitive to
CAF‐CM in cell proliferation, migration,40,41 and signaling altera-
tions,38,42 compared with other breast cancer cells. A variety of
F IGURE 5 FGF2‐induced breast cancer cell proliferation and migration mediated through FGFR1 activation. A, MDA‐MB‐231 cells were treated
with FGF2 (20 ng/mL) for indicated time periods. The expression of Cyclin D1 was assessed byWestern blot analysis. B and C, MDA‐MB‐231 cells were
transfected with scrambled or FGFR1 si‐RNA for 24 hour. Cells were then incubated with 20 ng/mL of FGF2 for 3 hour. The expression of Cyclin D1 was
assessed by RT‐PCR (B) andWestern blot (C) analyses. D, The effects of FGF2 on Akt activation through phosphorylation was assessed byWestern blot
analysis. E, Scrambled or FGFR1‐knockdownMDA‐MB‐231 cells were exposed to 20ng/mL of FGF2 for 24hour. The ability of cancer cell migration was
measured by the wound healing assay as described in Materials and Methods. Data are means ± SD. FGF, fibroblast growth factor; FGFR, fibroblast
growth factor receptor; RT‐PCR, reverse transcription‐polymerase chain reaction; siRNA, small interfering RNA. *P< .05; **P< .01; ***P< .005
[Color figure can be viewed at wileyonlinelibrary.com]
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cytokines including CXCL12 (SDF1),11 HGF,43 and IL‐644 are secreted
from CAFs, and contribute to cancer progression.
Although many studies have revealed FGF2 secretion from
CAFs,14,15,30,45 its role in cancer development and progression has
not been fully elucidated. FGF2 is a member of FGF family, and an
elevated level of its stromal expression is closely correlated with
breast cancer progression and recurrence.46 Microarray analysis of
CAFs from TNBC, ER‐positive and HER2‐positive breast cancer pa-
tients showed increased FGF2 expression in CAFs from TNBC
whereas FGFR1 was downregulated in the same cells. This indicates
that there is a possible paracrine signaling between CAFs and TNBC
cells.47
FGFR1 is a cognate receptor of FGF2, which is also called basic
FGFR or bFGFR,48 and its amplification drives chemoresistance in
breast cancer.49 FGFR1‐targeting small molecules, such as FIIN‐2 and
FIIN‐4, covalently interact with a conserved cysteine present in the
P‐loop of FGFR1, thereby reducing the metastatic potential of breast
cancer cells.50 Autocrine FGF2‐FGFR1 activation in bone marrow
stromal cells increased the secretion of FGF2‐laden exosomes, which
were subsequently endocytosed by leukemia cells, and thereby
protected leukemia cells from tyrosine kinase inhibitors.51
We noticed that FGFR1 was expressed primarily in basal‐like
MDA‐MB‐231 and MDA‐MB‐468 breast cancer cells. Although these
cells express FGFR1, transmission of FGFR1‐mediated signaling, such
as FRS2α phosphorylation, cannot be achieved in the absence of
external stimulation. Thus, it is likely that these cells require exo-
genous inducers, such as FGF2 released by CAFs, for their survival in
the tumor microenvironment. We observed the expression of FGF2
and FGFR1 in activated fibroblasts and TNBC cells, respectively.
FGF2‐neutralizing antibody treatment of MDA‐MB‐231 cells
F IGURE 6 Stimulation of tumor formation by activated fibroblasts via FGFR1 signaling. A, The representative photographs of xenograft tumors
grown in nude mice. B, Growth curves of xenograft tumors. Mice were coinjected subcutaneously with fibroblasts and MDA‐MB‐231 breast cancer
cells. Group1 (G1): unactivated control‐CCD‐1068sk fibroblasts and shmock‐MDA‐MB‐231 cells. Group2 (G2): control‐CCD‐1068sk fibroblasts and
shFGFR1‐MDA‐MB‐231 cells. Group3 (G3): TGF‐β‐activated CCD‐1068sk fibroblasts and shmock‐MDA‐MB‐231 cells. Group4 (G4): TGF‐β‐activated
CCD‐1068sk fibroblasts and shFGFR1‐MDA‐MB‐231 cells. Tumor volume was measured by using a digital caliper and calculated by the formula;
0.5 × (length) × (width)2. C, Appearance of tumors from each treatment group. D, Immunohistochemical analysis in mouse xenograft tumors.
A complex collagen network was detected by a blue stain (arrows) in Masson's trichrome staining. The expression of Cyclin D1 and PCNA was
analyzed by immunohistochemistry as described in Materials and Methods. Bars = 100 μm. E, The protein expression of FGFR1 and Cyclin D1 was
measured by Western blot analysis. Data are means ± SD. FGFR, fibroblast growth factor receptor; PCNA, proliferating cell nuclear antigen; TGF‐β,
Transforming growth factor beta. *P < .05; **P < .01; ***P < .005 [Color figure can be viewed at wileyonlinelibrary.com]
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attenuated CAF‐CM‐induced FRS2α phosphorylation responsible for
FGFR1 signaling. These findings suggest that FGF2 derived from
activated fibroblasts stimulates TNBC cell proliferation and migra-
tion through activation of FGFR1 signaling.
CAFs can affect not only cancer cells but also other stromal cells,
such as tumor associated macrophages and endothelial cells by secreting
FGF2, consequently modulating dynamic tumor microenvironmental
conditions, such as promotion of immuno‐suppressive status and neo‐
vascularization.29 In an immuno‐suppressive tumor condition, antitumor
agents have limited activity to kill cancer cells.52
The results from our present study suggest that CAFs promote
breast cancer cell proliferation, migration, and invasion via the paracrine
FGF2‐FGFR1 axis. In line with our supposition, Su et al14 have identified
FGF2 and other paracrine secreted factors that regulate breast carci-
noma cell mitogenesis. In another study, the activation of FGF2‐FGFR1
paracrine signaling triggered the expression of the connective tissue
growth factor, leading to the migration and invasion of breast cancer
cells.46 The results demonstrated herein and in the aforementioned
studies provide a novel molecular mechanism by which CAF‐derived
soluble factors affect the growth and progression of breast cancer cells.
The FGF2‐FGFR1 paracrine loop is important in the cross‐talk between
cancer cells and CAFs in the breast tumor microenvironment. There-
fore, the FGF2‐FGFR1 axis could be exploited as a prospective ther-
apeutic target to efficiently disrupt the tumor‐promoting interaction
between CAFs and breast cancer cells (Figure 7).
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